Innovate

Veterinary medicines are commonly used by veterinarians, farmers and pet owners to treat and prevent animal diseases. Like what is already in place for pharmaceutical products within ICH M7, a guideline is also available for veterinary medicinal products to ensure appropriate control of mutagenic impurities. The guideline provides a practical framework that is applicable to […]

New approach methodologies (NAMs) are non-animal methods – including in chemico/in vitro assays and in silico predictions – which are increasingly being used to assess the safety of cosmetic ingredients and products. A next generation risk assessment (NGRA) framework for skin sensitisation has recently been developed, and case studies highlighting the role of NAMs, defined

We are delighted to announce our participation in the Animal-Free Safety Assessment for Cosmetics (AFSA) Masterclass. Launched in March 2023, this free, online training programme is designed to build capacity and confidence in animal-free safety assessment of cosmetics and ingredients. Over the last three years, our scientists have helped to build a one-of-a-kind educational course

We are delighted to share our vital new article ‘Establishing best practice for the application and support of solubility purge factors’ which was recently published in Organic Process Research & Development (OPRD). The paper has been written by Lhasa Principal Scientist Michael Burns, alongside industry expert co-authors from AstraZeneca, GSK, Hoffman LaRoche and other forward

Mutagenic impurities can be expected in any drug product; however, this is not a concern providing they are present below the safe limit. The objective of a carcinogenicity study is to identify compounds that can cause tumours in animals, which is imperative to understanding the cancer risk posed to humans. ICH M7 in practice The

Evaluating the potential toxicity of chemicals is an important part of the drug development process. Optimizing a data set that provides quality over quantity is critical in the search for suitable drug candidates. Developed by our scientists, Vitic is a chemical database and information management system that provides rapid access to high-quality toxicity data from

By 2025, 36% of world data will be healthcare data. (Yes, thirty-six percent!). Considering this statistic, now more than ever, it is important that we are working to ensure existing data is utilised to make better safety assessment decisions more quickly – whilst also relying less on animal testing. Within many sectors of the life

The nitrosamine crisis first erupted in July 2018, when the FDA announced voluntary recall of several drugs containing Valsartan: a medicine used to treat high blood pressure and heart failure. Due to an unreported change in synthesis of Valsartan, the potentially cancer-causing chemical N-nitrosodimethylamine (or NDMA) was detected in the marketed drug product. This resulted

With technical input from Andrew Thresher. Would your toxicology assessments benefit from free access to long-term carcinogenicity study data? The Lhasa Carcinogenicity Database (LCDB) is a widely used, free resource of long-term carcinogenicity study data. In this article we explore 5 things you should know about the data in the LCDB. 1. The Lhasa Carcinogenicity

When assessing the mutagenic potential of drug impurities in silico, the ICH M7 guideline states that two complementary (Q)SAR prediction methodologies should be applied. A provision for the application of ‘expert knowledge’ is also mentioned within the guideline. However, as (Q)SAR models continue to be updated and their predictive performance and structural coverage improves, this raises